The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders
Abstract
Mitochondrial disorders share common cellular consequences: (1) decreased ATP production; (2) increased reliance on alternative anaerobic energy sources; and (3) increased production of reactive oxygen species. The purpose of the present study was to determine the effect of a combination therapy (creatine monohydrate, coenzyme Q 10, and lipoic acid to target the above‐mentioned cellular consequences) on several outcome variables using a randomized, double‐blind, placebo‐controlled, crossover study design in patients with mitochondrial cytopathies. Three patients had mitochondrial encephalopathy, lactic acidosis, and stroke‐like episodes (MELAS), four had mitochondrial DNA deletions (three patients with chronic progressive external ophthalmoplegia and one with Kearns–Sayre syndrome), and nine had a variety of other mitochondrial diseases not falling into the two former groups. The combination therapy resulted in lower resting plasma lactate and urinary 8‐isoprostanes, as well as attenuation of the decline in peak ankle dorsiflexion strength in all patient groups, whereas higher fat‐free mass was observed only in the MELAS group. Together, these results suggest that combination therapies targeting multiple final common pathways of mitochondrial dysfunction favorably influence surrogate markers of cellular energy dysfunction. Future studies with larger sample sizes in relatively homogeneous groups will be required to determine whether such combination therapies influence function and quality of life. Muscle Nerve, 2006
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We found that α-lipoic acid exerts significant neuroprotective effects in transgenic mouse models of HD and ALS128, 187, 188.”
From Mitochondrial Approaches for Neuroprotection (2008) · cites this paper as [128]
Citations
Cites
Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation
Harris, R. C., Söderlund, K., & Hultman, E. (1992) · Clinical Science · doi:10.1042/cs0830367 · Cited by 1,168
Isoprostanes: markers and mediators of oxidative stress
Montuschi, P., Barnes, P. J., & Roberts, L. J. (2004) · The FASEB Journal · doi:10.1096/fj.04-2330rev · Cited by 747
Lipoic Acid as a Potential Therapy for Chronic Diseases Associated with Oxidative Stress
Smith, A. R. W., Shenvi, S. V., Widlansky, M. E., Suh, J.-I., & Hagen, T. M. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043365387 · Cited by 461
Direct antioxidant properties of creatine
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6164 · Cited by 448
F 2 -Isoprostanes as markers of oxidative stress in vivo : An overview
Milne, G. L., Musiek, E. S., & Morrow, J. D. (2005) · Biomarkers · doi:10.1080/13547500500216546 · Cited by 323
Brose, A., Parise, G., & Tarnopolsky, M. A. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.1.b11 · Cited by 274
Self-citationA randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies
Tarnopolsky, M. A., Roy, B. D., & MacDonald, J. R. (1997) · Muscle & Nerve · doi:10.1002/(sici)1097-4598(199712)20:12 · Cited by 246
Self-citationTarnopolsky, M. A., & Beal, M. F. (2001) · Annals of Neurology · doi:10.1002/ana.1028 · Cited by 244
Self-citationIsoprostanes and related products of lipid peroxidation in neurodegenerative diseases
Montine, K. S., Quinn, J. F., Zhang, J., Fessel, J. P., Roberts, L. J., Morrow, J. D., & Montine, T. J. (2003) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2003.10.010 · Cited by 242
Sestili, P., Martinelli, C., Bravi, G., Piccoli, G., Curci, R., Battistelli, M., Falcieri, E., Agostini, D., Gioacchini, A. M., & Stocchi, V. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.10.035 · Cited by 220
Flagged first, then by citations
Cited by
Sorted by citations
Gorman, G. S., Chinnery, P. F., DiMauro, S., Hirano, M., Koga, Y., McFarland, R., Suomalainen, A., Thorburn, D. R., Zeviani, M., & Turnbull, D. M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.80 · Cited by 1,650
The creatine kinase system and pleiotropic effects of creatine
Wallimann, T., Tokarska-Schlattner, M., & Schlattner, U. (2011) · Amino Acids · doi:10.1007/s00726-011-0877-3 · Cited by 797
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633
Parikh, S., Goldstein, A., Koenig, M. K., Scaglia, F., Enns, G. M., Saneto, R., Anselm, I., Cohen, B. H., Falk, M. J., Greene, C., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.177 · Cited by 607
Self-citationMELAS syndrome: Clinical manifestations, pathogenesis, and treatment options
El‐Hattab, A. W., Adesina, A. M., Jones, J. Y., & Scaglia, F. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.06.004 · Cited by 635
Treatment for mitochondrial disorders
Pfeffer, G., Majamaa, K., Turnbull, D. M., Thorburn, D. R., & Chinnery, P. F. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004426.pub3 · Cited by 501
Wu, G. (2020) · Amino Acids · doi:10.1007/s00726-020-02823-6 · Cited by 485
Mitochondrial Diseases of the Brain
Chaturvedi, R. K., & Beal, M. F. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.03.018 · Cited by 426
Self-citationFunctions and effects of creatine in the central nervous system
Andres, R. H., Ducray, A., Schlattner, U., Wallimann, T., & Widmer, H. R. (2008) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2008.02.035 · Cited by 389
Mitochondrial Encephalopathy, Lactic Acidosis, and Strokelike Episodes
Sproule, D. M., & Kaufmann, P. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1444.011 · Cited by 352
What Is Nuclear Factor Kappa B (NF-κB) Doing in and to the Mitochondrion?
Albensi, B. C. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00154 · Cited by 341
El‐Hattab, A. W., & Scaglia, F. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0177-6 · Cited by 355
Gardner, A., & Boles, R. G. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.030 · Cited by 333
Mitochondrial DNA maintenance defects
El‐Hattab, A. W., Craigen, W. J., & Scaglia, F. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.02.017 · Cited by 296
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294
Self-citationThe Neuro-ophthalmology of Mitochondrial Disease
Fraser, J. A., Biousse, V., & Newman, N. J. (2010) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.10.002 · Cited by 256
Niyazov, D. M., Kahler, S. G., & Frye, R. E. (2016) · Molecular Syndromology · doi:10.1159/000446586 · Cited by 245
Sestili, P., Martinelli, C., Colombo, E., Barbieri, E., Potenza, L., Sartini, S., & Fimognari, C. (2011) · Amino Acids · doi:10.1007/s00726-011-0875-5 · Cited by 212
Therapies for mitochondrial diseases and current clinical trials
El‐Hattab, A. W., Zarante, A. M., Almannai, M., & Scaglia, F. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.09.009 · Cited by 188
Creatine for treating muscle disorders
Kley, R. A., Tarnopolsky, M. A., & Vorgerd, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004760.pub4 · Cited by 169
Self-citationNew treatments for mitochondrial disease—no time to drop our standards
Pfeffer, G., Horváth, R., Klopstock, T., Mootha, V. K., Suomalainen, A., Koene, S., Hirano, M., Zeviani, M., Bindoff, L. A., Yu‐Wai‐Man, P., et al. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.129 · Cited by 166
Diagnosis and treatment of mitochondrial myopathies
Pfeffer, G., & Chinnery, P. F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.605389 · Cited by 163
Tarnopolsky, M. A. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.05.001 · Cited by 161
Self-citationKumar, A., & Singh, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00206 · Cited by 157
Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
Karaa, A., Haas, R., Goldstein, A. C., Vockley, J. E., Weaver, W. D., & Cohen, B. H. (2018) · Neurology · doi:10.1212/wnl.0000000000005255 · Cited by 152
Wesselink, E., Koekkoek, W. A. C., Grefte, S., Witkamp, R. F., & van Zanten, A. R. H. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.08.032 · Cited by 149
Tarnopolsky, M. A., Zimmer, A., Paikin, J. S., Safdar, A., Aboud, A., Pearce, E., Roy, B. D., & Doherty, T. J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000991 · Cited by 148
Self-citationCoenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Mancuso, M., Orsucci, D., Volpi, L., Calsolaro, V., Siciliano, G., Spinelli, A., Correale, C., Szabó, H., & Montorsi, M. (2009) · Current Drug Targets · doi:10.2174/138945010790031018 · Cited by 139
A randomized trial of coenzyme Q 10 in mitochondrial disorders
Glover, E. I., Martin, J. C., Maher, A. C., Thornhill, R. E., Moran, G. R., & Tarnopolsky, M. A. (2010) · Muscle & Nerve · doi:10.1002/mus.21758 · Cited by 137
Self-citationAntioxidants halt axonal degeneration in a mouse model of X‐adrenoleukodystrophy
López‐Erauskin, J., Fourcade, S., Galino, J., Ruíz, M., Schlüter, A., Naudí, A., Jové, M., Portero‐Otín, M., Pamplona, R., Ferrer, I., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22363 · Cited by 135
Perspectives on Exertional Rhabdomyolysis
Rawson, E. S., Clarkson, P. M., & Tarnopolsky, M. A. (2017) · Sports Medicine · doi:10.1007/s40279-017-0689-z · Cited by 133
Self-citationPower of mitochondrial drug delivery systems to produce innovative nanomedicines
Yamada, Y., Satrialdi, S., Hibino, M., Sasaki, D., Abe, J., & Harashima, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.010 · Cited by 129
Oxidative Stress and Mitochondrial Dysfunction in Down Syndrome
Pagano, G., & Castello, G. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0653-2_22 · Cited by 125
Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines
de Barcelos, I. P., Shadiack, E., Ganetzky, R. D., & Falk, M. J. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000954 · Cited by 116
Galea, E., Launay, N., Portero-Otin, M., Ruiz, M., Pamplona, R., Aubourg, P., Ferrer, I., & Pujol, A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.02.005 · Cited by 108
Pallardó, F. V., Lloret, A., Lebel, M., d’Ischia, M., Cogger, V. C., Couteur, D. G. L., Gadaleta, M. N., Castello, G., & Pagano, G. (2010) · Biogerontology · doi:10.1007/s10522-010-9269-4 · Cited by 107
Treatment of Mitochondrial Disorders
Avula, S., Parikh, S., Demarest, S., Kurz, J. E., & Gropman, A. L. (2014) · Current Treatment Options in Neurology · doi:10.1007/s11940-014-0292-7 · Cited by 108
Metabolic Myopathies: Update 2009
van Adel, B. A., & Tarnopolsky, M. A. (2009) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0b013e3181903126 · Cited by 105
Self-citationLiver Disease in Mitochondrial Disorders
Lee, W. S., & Sokol, R. J. (2007) · Seminars in Liver Disease · doi:10.1055/s-2007-985071 · Cited by 106
Mitochondrial dysfunction in ocular disease: Focus on glaucoma
Kamel, K., Farrell, M., & O'Brien, C. J. (2017) · Mitochondrion · doi:10.1016/j.mito.2017.05.004 · Cited by 98
Inherited Metabolic Disorders and Stroke Part 1
Testai, F. D., & Gorelick, P. B. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.309 · Cited by 98
Mitochondrial Transplantation as a Novel Therapeutic Strategy for Mitochondrial Diseases
Park, A., Oh, M., Lee, S. H., Oh, K., Lee, E., Lee, S.-W., Bae, K., Han, B., & Kim, W. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094793 · Cited by 97
El‐Hattab, A. W., & Scaglia, F. (2016) · Cell Calcium · doi:10.1016/j.ceca.2016.03.003 · Cited by 98
Review of clinical trials for mitochondrial disorders: 1997-2012
Kerr, D. S. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0176-7 · Cited by 96
Clemente‐Suárez, V. J., Beltrán-Velasco, A. I., Ramos‐Campo, D. J., Mielgo‐Ayuso, J., Nikolaidis, P. Τ., Belando‐Pedreño, N., & Tornero-Aguilera, J. F. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113667 · Cited by 107
Kuruppu, D. K., & Matthews, B. R. (2013) · Seminars in Neurology · doi:10.1055/s-0033-1359320 · Cited by 106
DiMauro, S., & Rustin, P. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.015 · Cited by 94
The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease
Haas, R. H. (2007) · Mitochondrion · doi:10.1016/j.mito.2007.03.008 · Cited by 92
Therapeutic Options in Hereditary Optic Neuropathies
Amore, G., Romagnoli, M., Carbonelli, M., Barboni, P., Carelli, V., & Morgia, C. L. (2020) · Drugs · doi:10.1007/s40265-020-01428-3 · Cited by 96
Mitochondrial disorders in children: toward development of small‐molecule treatment strategies
Koopman, W. J. H., Beyrath, J., Fung, C., Koene, S., Rodenburg, R. J., Willems, P. H. G. M., & Smeitink, J. A. M. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506131 · Cited by 90
Steriade, C., Andrade, D. M., Faghfoury, H., Tarnopolsky, M. A., & Tai, P. C. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.01.009 · Cited by 85
Self-citationGalino, J., Ruíz, M., Fourcade, S., Schlüter, A., López‐Erauskin, J., Guilera, C., Jové, M., Naudí, A., García‐Arumí, E., Andreu, A. L., et al. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3877 · Cited by 85
Mitochondrial disorders: Challenges in diagnosis & treatment
Kumarasamy Thangaraj, K., Khan, N., Govindaraj, P., & Meena, A. (2015) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.154489 · Cited by 88
Nonpharmacologic Treatment of Dyslipidemia
Houston, M. C., Fazio, S., Chilton, F. H., Wise, D. E., Jones, K. B., Barringer, T. A., & Bramlet, D. A. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.02.002 · Cited by 85
Sestili, P., Barbieri, E., Martinelli, C., Battistelli, M., Guescini, M., Vallorani, L., Casadei, L., D'Emilio, A., Falcieri, E., Piccoli, G., et al. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800504 · Cited by 84
Current and Emerging Clinical Treatment in Mitochondrial Disease
Tinker, R. J., Lim, A. Z., Stefanetti, R. J., & McFarland, R. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-020-00510-6 · Cited by 83
Bottani, E., Lamperti, C., Prigione, A., Tiranti, V., Persico, N., & Brunetti, D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12111083 · Cited by 89
Wallimann, T., Tokarska-Schlattner, M., Neumann, D., Epand, R. M., Epand, R. F., Andres, R. H., Widmer, H. R., Hornemann, T., Saks, V. A., Agarkova, I., et al. (2007) · Wiley eBooks · doi:10.1002/9783527621095.ch7 · Cited by 83
The Psychiatric Presentation of Mitochondrial Disorders in Adults
Anglin, R. E., Tarnopolsky, M. A., Mazurek, M. F., & Rosebush, P. I. (2012) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/appi.neuropsych.11110345 · Cited by 77
Self-citationDevelopment of pharmacological strategies for mitochondrial disorders
Kanabus, M., Heales, S., & Rahman, S. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12456 · Cited by 81
Nierenberg, A. A., Kansky, C., Brennan, B. P., Shelton, R. C., Perlis, R. H., & Iosifescu, D. V. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412449303 · Cited by 78
Mitochondrial dysfunction in central nervous system white matter disorders
Morató, L., Bertini, E., Verrigni, D., Ardissone, A., Ruíz, M., Ferrer, I., Uziel, G., & Pujol, A. (2014) · Glia · doi:10.1002/glia.22670 · Cited by 77
Galeshkalami, N. S., Abdollahi, M. R., Najafi, R., Baeeri, M., Jamshidzade, A., Falak, R., Gholami, M. D., Hassanzadeh, G., Mokhtari, T., Hassani, S., et al. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.10.055 · Cited by 70
Polyák, E., Ostrovsky, J., Peng, M., Dingley, S. D., Tsukikawa, M., Kwon, Y. J., McCormack, S. E., Bennett, M. J., Xiao, R., Seiler, C., et al. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.02.013 · Cited by 69
Clinical Use of Creatine in Neuromuscular and Neurometabolic Disorders
Tarnopolsky, M. A. (2007) · Subcellular Biochemistry · doi:10.1007/978-1-4020-6486-9_10 · Cited by 67
Self-citationCreatine and Creatine Kinase in Health and Disease
Salomons, G. S., & Wyss, M. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4020-6486-9 · Cited by 67
Nutritional interventions in primary mitochondrial disorders: Developing an evidence base
Camp, K. M., Krotoski, D., Parisi, M. A., Gwinn, K. A., Cohen, B. H., Cox, C. S., Enns, G. M., Falk, M. J., Goldstein, A. C., Gopal-Srivastava, R., et al. (2016) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2016.09.002 · Cited by 59
Mitochondrial therapies for Parkinson's disease
Thomas, B., & Beal, M. F. (2010) · Movement Disorders · doi:10.1002/mds.22781 · Cited by 62
Self-citationTarnopolsky, M. A. (2016) · Continuum · doi:10.1212/con.0000000000000403 · Cited by 61
Self-citationTreatment of hereditary optic neuropathies
Newman, N. J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.167 · Cited by 61
Santa, K. M. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.11.1179 · Cited by 64
Oxidative Stress and Down Syndrome. Do Antioxidants Play a Role in Therapy?
Muchová, J., Žitňanová, I., & Ďuračková, Z. (2014) · Physiological Research · doi:10.33549/physiolres.932722 · Cited by 63
Mitochondrial functions and rare diseases
Dard, L., Blanchard, W., Hubert, C., Lacombe, D., & Rossignol, R. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.100842 · Cited by 65
Marin, S. E., Mesterman, R., ROBINSON, B. J., Rodenburg, R. J., Smeitink, J. A. M., & Tarnopolsky, M. A. (2012) · Gene · doi:10.1016/j.gene.2012.12.024 · Cited by 59
Self-citationArginine and Citrulline for the Treatment of MELAS Syndrome
El‐Hattab, A. W., Almannai, M., & Scaglia, F. (2017) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1177/2326409817697399 · Cited by 60
Yang, M., Xu, L., Xu, C., Cui, Y., Jiang, S., Dong, J., & Liao, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.728043 · Cited by 57
Cohen, B. H., Chinnery, P. F., & Copeland, W. C. (2014) · Europe PMC (PubMed Central) · Cited by 57
Cornish, S. M., Candow, D. G., Jantz, N., Chilibeck, P. D., Little, J. P., Forbes, S. C., Abeysekara, S., & Zello, G. A. (2009) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.19.1.79 · Cited by 59
Kaufman, K. R., Zuber, N., Rueda-Lara, M. A., & Tobia, A. (2010) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2010.05.020 · Cited by 53
Recent topics: the diagnosis, molecular genesis, and treatment of mitochondrial diseases
Murayama, K., Shimura, M., Liu, Z., Okazaki, Y., & Ohtake, A. (2018) · Journal of Human Genetics · doi:10.1038/s10038-018-0528-6 · Cited by 53
Mitochondrial response to controlled nutrition in health and disease
Schiff, M., Bénit, P., Coulibaly, A., Loublier, S., El‐Khoury, R., & Rustin, P. (2011) · Nutrition Reviews · doi:10.1111/j.1753-4887.2010.00363.x · Cited by 53
Oxidative Stress Treatment for Clinical Trials in Neurodegenerative Diseases
Ienco, E. C., LoGerfo, A., Carlesi, C., Orsucci, D., Ricci, G., Mancuso, M., & Siciliano, G. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110164 · Cited by 56
Creatine as a therapeutic strategy for myopathies
Tarnopolsky, M. A. (2011) · Amino Acids · doi:10.1007/s00726-011-0876-4 · Cited by 52
Self-citationIsoprostanes in fetal and neonatal health and disease
Belik, J., González-Luis, G. E., Pérez‐Vizcaíno, F., & Villamor, E. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.10.043 · Cited by 52
Fan, H., Lee, H.-F., Yue, C.-T., & Chi, C. (2021) · Life · doi:10.3390/life11111111 · Cited by 51
Toniolo, R. A., Silva, M., Fernandes, F. D. B. F., Amaral, J. A. D. M. S., Dias, R. D. S., & Lafer, B. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1817-5 · Cited by 50
Advances in primary mitochondrial myopathies
de Barcelos, I. P., Emmanuele, V., & Hirano, M. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000743 · Cited by 48
Therapy for mitochondrial disorders: Little proof, high research activity, some promise
Suomalainen, A. (2011) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2011.05.003 · Cited by 47
Genetics of ischaemic stroke in young adults
Terni, E., Giannini, N., Brondi, M., Montano, V., Bonuccelli, U., & Mancuso, M. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2014.12.004 · Cited by 46
Mitochondrial dysfunction in cognitive neurodevelopmental disorders: Cause or effect?
Anitha, A., Thanseem, I., Iype, M., & Thomas, S. V. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.01.002 · Cited by 47
Coenzyme Q10 and Neurological Diseases
Mancuso, M., Orsucci, D., Calsolaro, V., Choub, A., & Siciliano, G. (2009) · Pharmaceuticals · doi:10.3390/ph203134 · Cited by 46
Liu, Z., Triba, M. N., Amathieu, R., Lin, X., Bouchemal, N., Hantz, E., Moyec, L. L., & Savarin, P. (2019) · Critical Care · doi:10.1186/s13054-019-2456-z · Cited by 46
Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
Moreira, P. I., Cardoso, S. M., Pereira, C., Santos, M. S., & Oliveira, C. R. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824651 · Cited by 44
Therapeutic use of creatine in brain or heart ischemia: Available data and future perspectives
Perasso, L., Spallarossa, P., Gandolfo, C., Ruggeri, P., & Balestrino, M. (2013) · Medicinal Research Reviews · doi:10.1002/med.20255 · Cited by 43
The regulatory roles of aminoacyl-tRNA synthetase in cardiovascular disease
Zou, Y., Yang, Y., Fu, X., He, X., Liu, M., Zong, T., Li, X., Aung, L. H. H., Wang, Z., & Yu, T. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.06.003 · Cited by 43
Mitochondrial Energy Depletion in Depression with Somatization
Gardner, A., & Boles, R. G. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112891 · Cited by 44
Alpha-lipoic acid in the treatment of psychiatric and neurological disorders: a systematic review
de Sousa, C. N. S., Leite, C. M. G. D. S., Medeiros, I. D. S., Vasconcelos, L. C., Cabral, L. M., Patrocínio, C. F. V., Patrocínio, M. L. V., Mouaffak, F., Kébir, O., Macêdo, D. S., et al. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0344-x · Cited by 42
Abadi, A., Crane, J. D., Ogborn, D. I., Hettinga, B. P., Akhtar, M., Stokl, A., MacNeil, L., Safdar, A., & Tarnopolsky, M. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060722 · Cited by 43
Self-citationCoenzyme Q10 in the Treatment of Mitochondrial Disease
Neergheen, V., Chalasani, A., Wainwright, L., Yubero, D., Montero, R., Artuch, R., & Hargreaves, I. P. (2017) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1177/2326409817707771 · Cited by 44
Mitochondrial Agents for Bipolar Disorder
Pereira, C. L., Chavarria, V., Vian, J., Ashton, M. M., Berk, M., Marx, W., & Dean, O. M. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy018 · Cited by 41
Metadata
- Authors
- Rodriguez, M. C., MacDonald, J. R., Mahoney, D. J., Parise, G., Beal, M. F., & Tarnopolsky, M. A.
- Affiliations
- McMaster University (CA)
- Cornell University (US)
- Corresponding author
- Tarnopolsky, Mark A.
- Venue
- Muscle & Nerve
- Publisher
- Wiley
- Published
- 2007-01-18
- Volume
- 35
- Issue
- 2
- Pages
- 235-242
- ISSN
- 0148-639X (ISSN-L)
- 1097-4598
- OpenAlex
- W2063874785
- Cited by
- 255
- References
- 39
- Citations by year
- 2026: 4 · 2025: 14 · 2024: 4 · 2023: 8 · 2022: 11 · 2021: 12 · 2020: 17 · 2019: 17 · 2018: 14 · 2017: 14 · 2016: 11 · 2015: 16 · 2014: 17 · 2013: 14 · 2012: 13
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Muscle & Nerve (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- mitochondrial disease, creatine monohydrate, coenzyme Q10, alpha-lipoic acid, combination therapy, MELAS, mitochondrial DNA deletions, chronic progressive external ophthalmoplegia, Kearns-Sayre syndrome, plasma lactate, reactive oxygen species, anaerobic metabolism, fat-free mass, ankle dorsiflexion strength, ATP production
- MeSH terms
- 8-Hydroxy-2'-Deoxyguanosine, Adolescent, Adult, Analysis of Variance, Antioxidants, Body Composition, Child, Coenzymes, Creatine, Creatinine, Deoxyguanosine, Double-Blind Method, Female, Humans, Thioctic Acid, Male, Middle Aged, Ubiquinone, Dinoprost, Cross-Over Studies, Mitochondrial Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
